Detail
Článek
Článek online
FT
Medvik - BMČ
  • Je něco špatně v tomto záznamu ?

Safety and efficacy of lower-sodium oxybate in adults with idiopathic hypersomnia: a phase 3, placebo-controlled, double-blind, randomised withdrawal study

Y. Dauvilliers, I. Arnulf, N. Foldvary-Schaefer, AM. Morse, K. Šonka, MJ. Thorpy, E. Mignot, P. Chandler, R. Parvataneni, J. Black, A. Sterkel, D. Chen, F. Skobieranda, RK. Bogan

. 2022 ; 21 (1) : 53-65. [pub] -

Jazyk angličtina Země Velká Británie

Typ dokumentu časopisecké články, práce podpořená grantem, komentáře

Perzistentní odkaz   https://www.medvik.cz/link/bmc22011532
E-zdroje Online Plný text

NLK ProQuest Central od 2002-05-01 do Před 2 měsíci
Nursing & Allied Health Database (ProQuest) od 2002-05-01 do Před 2 měsíci
Health & Medicine (ProQuest) od 2002-05-01 do Před 2 měsíci
Psychology Database (ProQuest) od 2002-05-01 do Před 2 měsíci

Odkazy

PubMed 34942138
DOI 10.1016/s1474-4422(21)00368-9
Knihovny.cz E-zdroje

BACKGROUND: Idiopathic hypersomnia is a central hypersomnolence disorder mainly characterised by excessive daytime sleepiness, with prolonged night-time sleep and pronounced sleep inertia. Until August, 2021, no medication had regulatory approval for the treatment of idiopathic hypersomnia. This study aimed to evaluate the safety and efficacy of lower-sodium oxybate in idiopathic hypersomnia. METHODS: This was a phase 3, multicentre (50 specialist sleep centres; six EU countries and the USA), placebo-controlled, double-blind, randomised withdrawal study. Participants (aged 18-75 years) with idiopathic hypersomnia (meeting criteria from the International Classification of Sleep Disorders, 2nd or 3rd editions) began lower-sodium oxybate treatment (oral solution once or twice nightly) in an open-label titration and optimisation period (10-14 weeks), followed by a 2-week, open-label, stable-dose period. After these open-label periods, participants were randomised (1:1) by means of an interactive web recognition system, stratified by participants' baseline medication use, to either placebo or lower-sodium oxybate (individually optimised dose; range 2·5-9·0 g/night) during a 2-week, double-blind, randomised withdrawal period. To maintain masking of treatment assignment, placebo and lower-sodium oxybate oral solutions were matched in volume, appearance, and taste. During the double-blind, randomised withdrawal period, participants and investigators were unaware of treatment assignments. The primary efficacy endpoint was change in Epworth Sleepiness Scale (ESS) score from the end of the stable-dose period to the end of the double-blind, randomised withdrawal period, which was assessed in the modified intention-to-treat population (defined as all participants who were randomly assigned, took at least one dose of study medication during the double blind, randomised withdrawal period, and had at least one set of post-randomisation assessments for the primary or key secondary endpoints). Adverse events were assessed in the safety population (defined as all participants who took at least one dose of study medication). This study is registered at ClinicalTrials.gov, NCT03533114, and at EU Clinical Trials, 2018-001311-79, and is complete. FINDINGS: Between Nov 27, 2018, and March 6, 2020, 154 participants were enrolled and comprised the safety population. ESS scores decreased from a mean of 15·7 (SD 3·8) at baseline to 6·1 (4·0) by the end of the stable-dose period. After the open-label periods, 115 participants were randomly assigned either placebo (n=59) or lower-sodium oxybate (n=56) and comprised the modified intention-to-treat population. During the double-blind, randomised withdrawal period, ESS scores increased (worsened) in participants randomly assigned to placebo but remained stable in those assigned to lower-sodium oxybate (least squares mean difference -6·5; 95% CI -8·0 to -5·0; p<0·0001). Treatment-emergent adverse events included nausea (34 [22%] of 154), headache (27 [18%] of 154), dizziness (19 [12%] of 154), anxiety (17 [11%] 154), and vomiting (17 [11%] 154). No deaths were reported during the study. INTERPRETATION: Lower-sodium oxybate treatment resulted in a clinically meaningful improvement in idiopathic hypersomnia symptoms, with an overall safety profile consistent with that reported for narcolepsy. Lower-sodium oxybate was approved in August, 2021, by the US Food and Drug Administration for the treatment of idiopathic hypersomnia in adults. FUNDING: Jazz Pharmaceuticals.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc22011532
003      
CZ-PrNML
005      
20220506130333.0
007      
ta
008      
220425s2022 xxk f 000 0|eng||
009      
AR
024    7_
$a 10.1016/S1474-4422(21)00368-9 $2 doi
035    __
$a (PubMed)34942138
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxk
100    1_
$a Dauvilliers, Yves $u Sleep and Wake Disorders Centre, Department of Neurology, Gui de Chauliac Hospital, Montpellier, France; University of Montpellier, INSERM Institute Neuroscience Montpellier, Montpellier, France. Electronic address: ydauvilliers@yahoo.fr
245    10
$a Safety and efficacy of lower-sodium oxybate in adults with idiopathic hypersomnia: a phase 3, placebo-controlled, double-blind, randomised withdrawal study / $c Y. Dauvilliers, I. Arnulf, N. Foldvary-Schaefer, AM. Morse, K. Šonka, MJ. Thorpy, E. Mignot, P. Chandler, R. Parvataneni, J. Black, A. Sterkel, D. Chen, F. Skobieranda, RK. Bogan
520    9_
$a BACKGROUND: Idiopathic hypersomnia is a central hypersomnolence disorder mainly characterised by excessive daytime sleepiness, with prolonged night-time sleep and pronounced sleep inertia. Until August, 2021, no medication had regulatory approval for the treatment of idiopathic hypersomnia. This study aimed to evaluate the safety and efficacy of lower-sodium oxybate in idiopathic hypersomnia. METHODS: This was a phase 3, multicentre (50 specialist sleep centres; six EU countries and the USA), placebo-controlled, double-blind, randomised withdrawal study. Participants (aged 18-75 years) with idiopathic hypersomnia (meeting criteria from the International Classification of Sleep Disorders, 2nd or 3rd editions) began lower-sodium oxybate treatment (oral solution once or twice nightly) in an open-label titration and optimisation period (10-14 weeks), followed by a 2-week, open-label, stable-dose period. After these open-label periods, participants were randomised (1:1) by means of an interactive web recognition system, stratified by participants' baseline medication use, to either placebo or lower-sodium oxybate (individually optimised dose; range 2·5-9·0 g/night) during a 2-week, double-blind, randomised withdrawal period. To maintain masking of treatment assignment, placebo and lower-sodium oxybate oral solutions were matched in volume, appearance, and taste. During the double-blind, randomised withdrawal period, participants and investigators were unaware of treatment assignments. The primary efficacy endpoint was change in Epworth Sleepiness Scale (ESS) score from the end of the stable-dose period to the end of the double-blind, randomised withdrawal period, which was assessed in the modified intention-to-treat population (defined as all participants who were randomly assigned, took at least one dose of study medication during the double blind, randomised withdrawal period, and had at least one set of post-randomisation assessments for the primary or key secondary endpoints). Adverse events were assessed in the safety population (defined as all participants who took at least one dose of study medication). This study is registered at ClinicalTrials.gov, NCT03533114, and at EU Clinical Trials, 2018-001311-79, and is complete. FINDINGS: Between Nov 27, 2018, and March 6, 2020, 154 participants were enrolled and comprised the safety population. ESS scores decreased from a mean of 15·7 (SD 3·8) at baseline to 6·1 (4·0) by the end of the stable-dose period. After the open-label periods, 115 participants were randomly assigned either placebo (n=59) or lower-sodium oxybate (n=56) and comprised the modified intention-to-treat population. During the double-blind, randomised withdrawal period, ESS scores increased (worsened) in participants randomly assigned to placebo but remained stable in those assigned to lower-sodium oxybate (least squares mean difference -6·5; 95% CI -8·0 to -5·0; p<0·0001). Treatment-emergent adverse events included nausea (34 [22%] of 154), headache (27 [18%] of 154), dizziness (19 [12%] of 154), anxiety (17 [11%] 154), and vomiting (17 [11%] 154). No deaths were reported during the study. INTERPRETATION: Lower-sodium oxybate treatment resulted in a clinically meaningful improvement in idiopathic hypersomnia symptoms, with an overall safety profile consistent with that reported for narcolepsy. Lower-sodium oxybate was approved in August, 2021, by the US Food and Drug Administration for the treatment of idiopathic hypersomnia in adults. FUNDING: Jazz Pharmaceuticals.
650    _2
$a mladiství $7 D000293
650    _2
$a dospělí $7 D000328
650    _2
$a senioři $7 D000368
650    12
$a poruchy nadměrné spavosti $x chemicky indukované $x farmakoterapie $7 D006970
650    _2
$a dvojitá slepá metoda $7 D004311
650    _2
$a lidé $7 D006801
650    12
$a idiopatická hypersomnie $x farmakoterapie $7 D020177
650    _2
$a lidé středního věku $7 D008875
650    12
$a oxybát sodný $x škodlivé účinky $7 D012978
650    _2
$a výsledek terapie $7 D016896
650    _2
$a mladý dospělý $7 D055815
655    _2
$a časopisecké články $7 D016428
655    _2
$a práce podpořená grantem $7 D013485
655    _2
$a komentáře $7 D016420
700    1_
$a Arnulf, Isabelle $u Sleep Disorder Unit, Pitié-Salpêtrière Hospital and Sorbonne University, Paris, France
700    1_
$a Foldvary-Schaefer, Nancy $u Cleveland Clinic Lerner College of Medicine, Cleveland, OH, USA
700    1_
$a Morse, Anne Marie $u Janet Weis Children's Hospital, Geisinger, Danville, PA, USA
700    1_
$a Šonka, Karel $u Department of Neurology, First Faculty of Medicine, Charles University and General University Hospital, Prague, Czech Republic
700    1_
$a Thorpy, Michael J $u Albert Einstein College of Medicine, Bronx, NY, USA
700    1_
$a Mignot, Emmanuel $u Stanford University Center for Narcolepsy, Redwood City, CA, USA
700    1_
$a Chandler, Patricia $u Jazz Pharmaceuticals, Palo Alto, CA, USA
700    1_
$a Parvataneni, Rupa $u Jazz Pharmaceuticals, Palo Alto, CA, USA
700    1_
$a Black, Jed $u Jazz Pharmaceuticals, Palo Alto, CA, USA; Stanford Center for Sleep Sciences and Medicine, Palo Alto, CA, USA
700    1_
$a Sterkel, Amanda $u Jazz Pharmaceuticals, Palo Alto, CA, USA
700    1_
$a Chen, Dan $u Jazz Pharmaceuticals, Palo Alto, CA, USA
700    1_
$a Skobieranda, Franck $u Jazz Pharmaceuticals, Philadelphia, PA, USA
700    1_
$a Bogan, Richard K $u University of South Carolina School of Medicine, Columbia, SC, USA
773    0_
$w MED00006921 $t The Lancet. Neurology $x 1474-4465 $g Roč. 21, č. 1 (2022), s. 53-65
856    41
$u https://pubmed.ncbi.nlm.nih.gov/34942138 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y p $z 0
990    __
$a 20220425 $b ABA008
991    __
$a 20220506130325 $b ABA008
999    __
$a ok $b bmc $g 1789241 $s 1162730
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2022 $b 21 $c 1 $d 53-65 $e - $i 1474-4465 $m Lancet neurology $n Lancet Neurol $x MED00006921
LZP    __
$a Pubmed-20220425

Najít záznam

Citační ukazatele

Možnosti archivace